The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model is a prognostic tool designed for stratifying patients with metastatic renal cell carcinoma into risk categories based on survival outcomes. The model incorporates six key clinical and laboratory parameters: time from diagnosis to systemic therapy less than one year, Karnofsky Performance Status less than 80%, hemoglobin levels below the lower limit of normal, corrected calcium levels above the upper limit of normal, neutrophil count above the upper limit of normal, and platelet count above the upper limit of normal. Each parameter contributes equally to the total score, which is then used to classify patients into three risk groups: favorable, intermediate, and poor. A score of zero corresponds to a favorable risk with a median survival of 43.2 months. A score of one or two indicates an intermediate risk with a median survival of 22.5 months. A score of three or more signifies a poor risk with a median survival of 7.8 months. The IMDC risk model aids clinicians in tailoring treatment strategies and informing patient prognosis in metastatic renal cell carcinoma.
Reference
Daniel Y C Heng, Wanling Xie, Meredith M Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9.
Open reference URL